{"id":4877,"date":"2019-10-09T09:01:21","date_gmt":"2019-10-09T07:01:21","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/agilent-opens-state-of-the-art-spectroscopy-site-in-the-uk\/"},"modified":"2019-10-09T09:01:21","modified_gmt":"2019-10-09T07:01:21","slug":"agilent-opens-state-of-the-art-spectroscopy-site-in-the-uk","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/agilent-opens-state-of-the-art-spectroscopy-site-in-the-uk\/","title":{"rendered":"Agilent Opens State-of-the-Art Spectroscopy Site in the UK"},"content":{"rendered":"
\n

\nNew facility will be a major research and development hub for molecular spectroscopy\n<\/p>\n

<\/a><\/p>\n

SANTA CLARA, Calif.–(BUSINESS WIRE)–Agilent Technologies, Inc.<\/a> (NYSE: A) today announced the opening of a new state-of-the-art facility for spectroscopy research and development at the Harwell Science and Innovation Campus in Oxfordshire, UK.\n<\/p>\n

\nA leader in molecular spectroscopy, the new Agilent site will be a major research and development hub for laser spectroscopy. It will also incorporate Agilent\u2019s Raman spectroscopy business, formerly known as Cobalt Light Systems (acquired by Agilent in 2017).\n<\/p>\n

\nAgilent is focusing on investment in two main areas: research and development to enable customers to perform better science, and harmonizing existing product lines to ensure an optimal customer experience. The site will also accommodate the company\u2019s Laser Spectroscopy Center of Excellence (LSCE), focusing on research and development in the field of vibrational spectroscopy.\n<\/p>\n

\nThe Harwell Campus spans 710 acres south of Oxford, UK, and is well-known as a hub for science and innovation. Harwell is home to over 200 organizations (public, private, and academic), 6,000 people, and \u00a32 billion of large-scale national science infrastructure. It is also where Agilent\u2019s proprietary Raman technologies were originally developed by Prof. Pavel Matousek, and his colleagues at the Science and Technology Facilities Council\u2019s Rutherford Appleton Laboratory, and where Cobalt Light Systems was first established.\n<\/p>\n

\n\u201cI’m proud to see Agilent, and the Raman business we helped to establish, growing strongly and returning to Harwell,\u201d said Prof. Pavel Matousek, a senior fellow at the Science and Technology Facilities Council (STFC) Central Laser Facility. \u201cThe new Agilent facility is perfectly located for collaboration between Agilent’s spectroscopy businesses and the large number of scientists and engineers we have at Harwell. I very much look forward to our future joint endeavors.\u201d\n<\/p>\n

\n\u201cThe growth in Agilent\u2019s molecular spectroscopy business created the need for a larger facility,\u201d said Phil Binns, vice president, and general manager of Agilent\u2019s Spectroscopy division. \u201cOur new flagship site will enable us to develop a truly unified approach to vibrational spectroscopy. The location will also facilitate greater collaboration with internationally acclaimed academic and scientific thought leaders based at this premier UK hub of scientific innovation.\u201d\n<\/p>\n

\nAgilent UK has more than 480 employees across the UK in manufacturing, sales, and service. Agilent\u2019s two manufacturing sites in Shropshire manufacture liquid chromatography columns, silica and polymeric particles, and magnetic beads for the clinical and diagnostic industry; as well as instruments for gel permeation chromatography. This investment in the UK strengthens Agilent\u2019s role as a leader in molecular spectroscopy.\n<\/p>\n

\nAbout Agilent Technologies<\/b>\n<\/p>\n

\nAgilent Technologies Inc. (NYSE: A) is a global leader in life sciences, diagnostics, and applied chemical markets. With more than 50 years of insight and innovation, Agilent instruments, software, services, solutions, and people provide trusted answers to customers’ most challenging questions. The company generated revenues of $4.91 billion in fiscal 2018 and employs 15,500 people worldwide. Information about Agilent is available at www.agilent.com<\/a>. To receive the latest Agilent news, subscribe to our Newsroom<\/a>. Follow Agilent on LinkedIn<\/a>, Twitter<\/a>, and Facebook<\/a>.\n<\/p>\n

\"\"<\/span><\/p>\n

Contacts<\/b> <\/p>\n

\nCatherine Kaye<\/b><\/strong>
Agilent Technologies
\n
+447775 410632
\n
catherine.kaye@agilent.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

New facility will be a major research and development hub for molecular spectroscopy SANTA CLARA, Calif.–(BUSINESS WIRE)–Agilent Technologies, Inc. (NYSE: A) today announced the opening of a new state-of-the-art facility for spectroscopy research and development at the Harwell Science and Innovation Campus in Oxfordshire, UK. A leader in molecular spectroscopy, the new Agilent site will … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-4877","6":"format-standard","7":"category-allgemein"},"yoast_head":"\nAgilent Opens State-of-the-Art Spectroscopy Site in the UK - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/agilent-opens-state-of-the-art-spectroscopy-site-in-the-uk\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Agilent Opens State-of-the-Art Spectroscopy Site in the UK - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"New facility will be a major research and development hub for molecular spectroscopy SANTA CLARA, Calif.–(BUSINESS WIRE)–Agilent Technologies, Inc. (NYSE: A) today announced the opening of a new state-of-the-art facility for spectroscopy research and development at the Harwell Science and Innovation Campus in Oxfordshire, UK. A leader in molecular spectroscopy, the new Agilent site will ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/agilent-opens-state-of-the-art-spectroscopy-site-in-the-uk\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2019-10-09T07:01:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20191009005190\/en\/33292\/21\/Agilent300_200w.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/agilent-opens-state-of-the-art-spectroscopy-site-in-the-uk\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/agilent-opens-state-of-the-art-spectroscopy-site-in-the-uk\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Agilent Opens State-of-the-Art Spectroscopy Site in the UK\",\"datePublished\":\"2019-10-09T07:01:21+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/agilent-opens-state-of-the-art-spectroscopy-site-in-the-uk\\\/\"},\"wordCount\":518,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/agilent-opens-state-of-the-art-spectroscopy-site-in-the-uk\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20191009005190\\\/en\\\/33292\\\/21\\\/Agilent300_200w.jpg\",\"articleSection\":[\"Allgemein\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/agilent-opens-state-of-the-art-spectroscopy-site-in-the-uk\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/agilent-opens-state-of-the-art-spectroscopy-site-in-the-uk\\\/\",\"name\":\"Agilent Opens State-of-the-Art Spectroscopy Site in the UK - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/agilent-opens-state-of-the-art-spectroscopy-site-in-the-uk\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/agilent-opens-state-of-the-art-spectroscopy-site-in-the-uk\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20191009005190\\\/en\\\/33292\\\/21\\\/Agilent300_200w.jpg\",\"datePublished\":\"2019-10-09T07:01:21+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/agilent-opens-state-of-the-art-spectroscopy-site-in-the-uk\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/agilent-opens-state-of-the-art-spectroscopy-site-in-the-uk\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/agilent-opens-state-of-the-art-spectroscopy-site-in-the-uk\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20191009005190\\\/en\\\/33292\\\/21\\\/Agilent300_200w.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20191009005190\\\/en\\\/33292\\\/21\\\/Agilent300_200w.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/agilent-opens-state-of-the-art-spectroscopy-site-in-the-uk\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Agilent Opens State-of-the-Art Spectroscopy Site in the UK\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Agilent Opens State-of-the-Art Spectroscopy Site in the UK - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/agilent-opens-state-of-the-art-spectroscopy-site-in-the-uk\/","og_locale":"en_US","og_type":"article","og_title":"Agilent Opens State-of-the-Art Spectroscopy Site in the UK - Pharma Trend","og_description":"New facility will be a major research and development hub for molecular spectroscopy SANTA CLARA, Calif.–(BUSINESS WIRE)–Agilent Technologies, Inc. (NYSE: A) today announced the opening of a new state-of-the-art facility for spectroscopy research and development at the Harwell Science and Innovation Campus in Oxfordshire, UK. A leader in molecular spectroscopy, the new Agilent site will ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/agilent-opens-state-of-the-art-spectroscopy-site-in-the-uk\/","og_site_name":"Pharma Trend","article_published_time":"2019-10-09T07:01:21+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20191009005190\/en\/33292\/21\/Agilent300_200w.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/agilent-opens-state-of-the-art-spectroscopy-site-in-the-uk\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/agilent-opens-state-of-the-art-spectroscopy-site-in-the-uk\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Agilent Opens State-of-the-Art Spectroscopy Site in the UK","datePublished":"2019-10-09T07:01:21+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/agilent-opens-state-of-the-art-spectroscopy-site-in-the-uk\/"},"wordCount":518,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/agilent-opens-state-of-the-art-spectroscopy-site-in-the-uk\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20191009005190\/en\/33292\/21\/Agilent300_200w.jpg","articleSection":["Allgemein"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/agilent-opens-state-of-the-art-spectroscopy-site-in-the-uk\/","url":"https:\/\/pharma-trend.com\/en\/agilent-opens-state-of-the-art-spectroscopy-site-in-the-uk\/","name":"Agilent Opens State-of-the-Art Spectroscopy Site in the UK - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/agilent-opens-state-of-the-art-spectroscopy-site-in-the-uk\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/agilent-opens-state-of-the-art-spectroscopy-site-in-the-uk\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20191009005190\/en\/33292\/21\/Agilent300_200w.jpg","datePublished":"2019-10-09T07:01:21+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/agilent-opens-state-of-the-art-spectroscopy-site-in-the-uk\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/agilent-opens-state-of-the-art-spectroscopy-site-in-the-uk\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/agilent-opens-state-of-the-art-spectroscopy-site-in-the-uk\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20191009005190\/en\/33292\/21\/Agilent300_200w.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20191009005190\/en\/33292\/21\/Agilent300_200w.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/agilent-opens-state-of-the-art-spectroscopy-site-in-the-uk\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Agilent Opens State-of-the-Art Spectroscopy Site in the UK"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/4877","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=4877"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/4877\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=4877"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=4877"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=4877"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}